艾博韦泰联合多替拉韦在初治艾滋病患者中的疗效分析

doi:10.19871/j.cnki.xfcrbzz.2022.03.004

摘要/Abstract

摘要： 目的分析艾博韦泰（ABT）联合多替拉韦（DTG）方案在初治艾滋病患者中的短期治疗后病毒载量及免疫功能变化,评估其疗效。方法收集2020年3月至2021年2月初治艾滋病患者186例,患者均接受ABT联合DTG治疗4周,观察患者体内病毒载量及免疫功能变化,并进行统计学分析。结果 ABT联合DTG治疗4周后患者的血浆HIV RNA明显降低(t=32.87,P<0.001),部分患者低于检测下限（<40copies/ml）;同时ABT联合DTG治疗4周后患者的免疫功能明显改善(P=0.001);并且无论基线HIV RNA水平高低,血清CD4+T淋巴细胞水平（P<0.001）、CD4+T/CD8+T淋巴细胞比值明显增高（P=0.005);尤其是高病毒载量患者,免疫功能恢复更加明显。结论对于初治艾滋病患者,无论基线HIV RNA水平高低,使用ABT联合DTG抗病毒治疗方案可在短期内快速降低患者体内血浆HIV RNA水平,改善患者免疫功能,使患者明显获益,为初治艾滋病患者提供有价值的治疗方案。

关键词: 艾滋病, 艾博韦泰, 多替拉韦, 疗效

Abstract: Objective To analyze the short-term efficacy and immune function of albuvirtide and dolutegravir in newly treated patients with AIDS,and to assess its efficacy. Method 186 patients with AIDS were collected from March 2020 to February 2021. Patients received ABT combined with DTG for 4 weeks,then observed the the curative effect and immune level,and statistically analyzed. Result After 4 weeks of ABT + DTG combined treatment, the plasma HIV RNA of patients was significantly decreased (t=32.87, P<0.001), and some patients were lower than the detection limit (<40 copies/ml). At the same time, the immune function of patients was significantly improved after 4 weeks of ABT + DTG combination therapy (P=0.001).The results showed that regardless of the baseline HIV RNA level, the serum CD4+T lymphocyte level (P<0.001) and CD4+T/CD8+T ratio were significantly increased (P=0.005). Immune function reconstruction is more obvious, especially in patients with high viral load. Conclusion For newly diagnosed AIDS patients, the ABT+DTG antiviral therapy can rapidly reduce HIV RNA levels and improve the immune function in the short term, regardless of the HIV viral load in the body. It can improve the immune function of patients, and make patients benefit significantly. It provide a valuable treatment plan for newly diagnosed AIDS patients.

Key words: Human immunodeficiency virus, Albuvirtide, Dolutegravir, Efficacy

朱迎春, 蔡琳. 艾博韦泰联合多替拉韦在初治艾滋病患者中的疗效分析[J]. 新发传染病电子杂志, 2022, 7(3): 18-21.

Zhu Yingchun, Cai Lin. Potential efficacy of combined use of albuvirtide and dolutegravir in newly diagnosed AIDS patients[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(3): 18-21.

参考文献

[1] LEE SA, SINCLAIR E, JAIN V, et al.Low proportions of CD28- CD8+T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection[J]. J Infect Dis, 2014, 210(3):374-82.
[2] N'TAKPE JB, GABILLARD D, MOH R, et al.Association between cellular HIV-1 DNA level and mortality in HIV-1 infected African adults starting ART with high CD4 counts[J].E Bio Medicine, 2020, 56:102815.
[3] TAO LL, LIU M, LI SM, et al.Condom use in combination with ART can reduce HIV incidence and mortality of PLWHA among MSM: a study from Beijing, China[J]. BMC Infect Dis, 2018, 18(1):124.
[4] KOREAN SOCIETY FOR AIDS. Summary of 2021 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans[J]. Infect Chemother, 2021, 53(3):592-616.
[5] 中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J] . 中华内科杂志, 2021, 60(12) : 1106-1128.
[6] WORLD HEALTH ORGANIZATION.Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection[R]. Geneva:World Health Organization,2018.
[7] LIU PT, TANG ZZ, LAN GH, et al.Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program[J]. Sci Rep, 2018, 8(1):3431.
[8] ZHANG F, DOU Z H, MA Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program[J].Ann Inter Med, 2009, 151(4):241-251, W-52.
[9] RANA A, CASTILLO-MANCILLA JR, TASHIMA KT, et al.Advances in Agents for the Treatment of HIV Infection[J]. Drugs,,2020, 80(6):535-545.
[10] NIE J, SUN F, HE X, et al.Tolerability and Adherence of Antiretroviral Regimens Containing Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China[J]. Infect Dis Ther, 2021, 10(4): 2611-2623.
[11] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心.中国艾滋病诊疗指南(2018版)[J/CD]. 新发传染病电子杂志,2019,4(2):65-84.
[12] CHONG H, YAO X, ZHANG C, et al.Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor[J]. PLoS One, 2012, 7(3):e32599.
[13] LALEZARI JP, HENRY K, O'HEARN M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America[J]. N Engl J Med, 2003, 348(22): 2175-2185.
[14] SU B, YAO C, ZHAO QX, et al.Efficacy and safety of the fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study[J]. Chin Med J (Engl), 2020, 133(24):2919-2927
[15] ZHANG H, JIN R, YAO C, et al.Combination of HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients[J]. AIDS Res Ther, 2016, 13:8
[16] 何盛华, 刘欢霞, 姚远, 等. 艾博韦泰方案在重症艾滋病患者中的临床疗效研究[J]. 四川医学, 2020, 41(9):893-897.
[17] YANG J, WEI G, HE Y, et al.Perioperative Antiretroviral Regimen for HIV/AIDS Patients Who Underwent Abdominal Surgery[J]. World J Surg, 2020, 44(6):1790-1797.